Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.63 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.63 |
| ▸ | MARK3 | P27448 | 1/20 | 0.63 |
| ▸ | PRKCI | P41743 | 1/20 | 0.63 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.63 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.63 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.63 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.63 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.63 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.63 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.63 |
| ▸ | HTR2C | P28335 | 9/20 | 0.54 |
| ▸ | QDPR | P09417 | 3/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5541194 | 0.98 | JAK2 (0.65) | JAK2PRKD3MARK3PRKCIPRKCD | |
| SCHEMBL2299855 | 0.88 | JAK2 (0.56) | JAK2PRKD3MARK3PRKCIPRKCD | |
| SCHEMBL19514110 | 0.84 | JAK2 (0.50) | JAK2PRKD3MARK3PRKCIPRKCD | |
| SCHEMBL25864472 | 0.83 | HTR2C (0.63) | JAK2PRKD3MARK3PRKCIPRKCD | |
| SCHEMBL10104548 | 0.79 | JAK2 (0.47) | JAK2PRKD3MARK3PRKCIPRKCD | |
| SCHEMBL894220 | 0.77 | QDPR (0.60) | HTR2CQDPRSIGMAR1 | |
| SCHEMBL14894193 | 0.77 | NISCH (0.50) | JAK2PRKD3MARK3PRKCIPRKCD | |
| SCHEMBL1472528 | 0.77 | HTR2C (0.69) | HTR2CQDPRSIGMAR1NISCH | |
| SCHEMBL3043133 | 0.77 | SCN9A (0.61) | HTR2CQDPRSIGMAR1HTR2ASCN9A | |
| SCHEMBL4699022 | 0.76 | JAK2 (0.50) | JAK2PRKD3MARK3PRKCIPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103450220-B | Nitroimidazole compound and application thereof in pharmacy | 上海阳帆医药科技有限公司 | 2017-02-08 | — | — | CN | disclosed |
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| CN-103450220-A | Novel nitroimidazole compound and application thereof in pharmacy | SHANGHAI SUN SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO LTD | 2013-12-18 | — | — | CN | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-2246329-A1 | 4(1H)-pyridinone derivatives and their use as antimalaria agents | Glaxo Group Limited (GB) | 2010-11-03 | — | — | EP | disclosed |
| EP-2246329-A1 | 4(1H)-pyridinone derivatives and their use as antimalaria agents | Glaxo Group Limited (GB) | 2010-11-03 | — | — | EP | disclosed |
| WO-2010081904-A1 | 4 ( 1H) -PYRIDINONE DERIVATIVES AND THEIR USE AS ANTIMALARIA AGENTS | GLAXO GROUP LIMITED (GB) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010081904-A1 | 4 ( 1H) -PYRIDINONE DERIVATIVES AND THEIR USE AS ANTIMALARIA AGENTS | GLAXO GROUP LIMITED (GB) | 2010-07-22 | — | — | WO | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | JAK2 4213/4885PRKD3 1783/4885MARK3 1779/4885 |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | JAK2 3387/4885PRKD3 4280/4885MARK3 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.